Diabetic kidney disease (DKD) is a leading cause of end-stage renal failure, with pathogenesis affecting both the glomerular and tubular compartments of the kidney. Identifying early, non-invasive, and common biomarkers for these compartments is critical for timely diagnosis and intervention. Versican (VCAN), a large extracellular matrix proteoglycan, has emerged as a promising biomarker in renal pathophysiology. This article investigates the expression and role of VCAN in both glomerular and tubular regions in DKD, supported by transcriptomic analyses, immunohistochemistry, and functional annotations. The findings highlight VCAN as a potential common diagnostic indicator of DKD progression and severity, offering a unified biomolecular perspective for clinical application. Keywords: Diabetic kidney disease; VCAN; biomarker;
